PNAS:AAV2 / 9病毒疗法延迟ALS疾病发作

2019-07-06 海北 MedSci原创

超氧化物歧化酶(SOD1)的突变引起肌萎缩侧索硬化症(ALS),这是一种神经退行性疾病,其特征在于上运动神经元和下运动神经元的丧失。

超氧化物歧化酶(SOD1)的突变引起肌萎缩侧索硬化症(ALS),这是一种神经退行性疾病,其特征在于上运动神经元和下运动神经元的丧失。

已有的研究显示,过表达突变体SOD1的转基因小鼠会发生麻痹,并将错误折叠的SOD1积聚到胞内细胞器的细胞质面上,包括线粒体和内质网(ER)。

最近,人们发现,巨噬细胞移动抑制因子(MIF)直接抑制突变体SOD1的错误折叠,以及其与细胞内膜的结合。此外,完全消除内源性MIF能够加速疾病发作和晚期疾病进展,以及缩短SOD1突变小鼠的寿命,在其脊髓内也能够检测到更高量的错误折叠的SOD1

基于这些发现,研究人员使用腺相关病毒(AAV)载体在突变体SOD1G93AloxSOD1G37R小鼠的脊髓中过表达MIF

数据显示,注射AAV2 / 9-MIF的小鼠的脊髓中MIF mRNA和蛋白质水平增加。此外,与注射AAV2 / 9-GFP或未注射的同窝小鼠相比,注射AAV2 / 9-MIFSOD1G93AloxSOD1G37R突变体小鼠显示出疾病发作的显着延迟和延长的存活。

此外,在这些小鼠的脊髓中,错误折叠的SOD1的累积减少。研究人员也没有观察到MIF上调对神经胶质过度活化的影响。

因此,该研究结果表明,MIFSOD1折叠和错误折叠机制中发挥重要作用,并强化了MIF作为体内错误折叠SOD1伴侣蛋白的假设,可能进一步暗示MIF上调调节特异性的潜在治疗作用。


原始出处:

Leyton-Jaimes MF et al. AAV2/9-mediated overexpression of MIF inhibits SOD1 misfolding, delays disease onset, and extends survival in mouse models of ALS. PNAS, 2019; doi: 10.1073/pnas.1904665116.


本文系梅斯医学(MedSci)原创编译整理,转载需授权

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1856320, encodeId=c8f21856320cd, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Mon Oct 28 07:08:00 CST 2019, time=2019-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024636, encodeId=c78e2024636a2, content=<a href='/topic/show?id=d3341696b8' target=_blank style='color:#2F92EE;'>#AAV2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1696, encryptionId=d3341696b8, topicName=AAV2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Sun Apr 19 03:08:00 CST 2020, time=2020-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1798838, encodeId=45671e9883800, content=<a href='/topic/show?id=82ebe065192' target=_blank style='color:#2F92EE;'>#疾病发作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70651, encryptionId=82ebe065192, topicName=疾病发作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Wed Jun 17 06:08:00 CST 2020, time=2020-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271862, encodeId=160212e1862f7, content=<a href='/topic/show?id=9fef169483' target=_blank style='color:#2F92EE;'>#AAV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1694, encryptionId=9fef169483, topicName=AAV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ba7103, createdName=xuqianhua, createdTime=Mon Jul 08 02:08:00 CST 2019, time=2019-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=369244, encodeId=84cc3692442c, content=向挑战病魔的科研人员致敬!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5171668917, createdName=坚强007, createdTime=Sun Jul 07 17:42:08 CST 2019, time=2019-07-07, status=1, ipAttribution=)]
    2019-10-28 drwjr
  2. [GetPortalCommentsPageByObjectIdResponse(id=1856320, encodeId=c8f21856320cd, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Mon Oct 28 07:08:00 CST 2019, time=2019-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024636, encodeId=c78e2024636a2, content=<a href='/topic/show?id=d3341696b8' target=_blank style='color:#2F92EE;'>#AAV2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1696, encryptionId=d3341696b8, topicName=AAV2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Sun Apr 19 03:08:00 CST 2020, time=2020-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1798838, encodeId=45671e9883800, content=<a href='/topic/show?id=82ebe065192' target=_blank style='color:#2F92EE;'>#疾病发作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70651, encryptionId=82ebe065192, topicName=疾病发作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Wed Jun 17 06:08:00 CST 2020, time=2020-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271862, encodeId=160212e1862f7, content=<a href='/topic/show?id=9fef169483' target=_blank style='color:#2F92EE;'>#AAV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1694, encryptionId=9fef169483, topicName=AAV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ba7103, createdName=xuqianhua, createdTime=Mon Jul 08 02:08:00 CST 2019, time=2019-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=369244, encodeId=84cc3692442c, content=向挑战病魔的科研人员致敬!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5171668917, createdName=坚强007, createdTime=Sun Jul 07 17:42:08 CST 2019, time=2019-07-07, status=1, ipAttribution=)]
    2020-04-19 lxg951
  3. [GetPortalCommentsPageByObjectIdResponse(id=1856320, encodeId=c8f21856320cd, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Mon Oct 28 07:08:00 CST 2019, time=2019-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024636, encodeId=c78e2024636a2, content=<a href='/topic/show?id=d3341696b8' target=_blank style='color:#2F92EE;'>#AAV2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1696, encryptionId=d3341696b8, topicName=AAV2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Sun Apr 19 03:08:00 CST 2020, time=2020-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1798838, encodeId=45671e9883800, content=<a href='/topic/show?id=82ebe065192' target=_blank style='color:#2F92EE;'>#疾病发作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70651, encryptionId=82ebe065192, topicName=疾病发作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Wed Jun 17 06:08:00 CST 2020, time=2020-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271862, encodeId=160212e1862f7, content=<a href='/topic/show?id=9fef169483' target=_blank style='color:#2F92EE;'>#AAV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1694, encryptionId=9fef169483, topicName=AAV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ba7103, createdName=xuqianhua, createdTime=Mon Jul 08 02:08:00 CST 2019, time=2019-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=369244, encodeId=84cc3692442c, content=向挑战病魔的科研人员致敬!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5171668917, createdName=坚强007, createdTime=Sun Jul 07 17:42:08 CST 2019, time=2019-07-07, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1856320, encodeId=c8f21856320cd, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Mon Oct 28 07:08:00 CST 2019, time=2019-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024636, encodeId=c78e2024636a2, content=<a href='/topic/show?id=d3341696b8' target=_blank style='color:#2F92EE;'>#AAV2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1696, encryptionId=d3341696b8, topicName=AAV2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Sun Apr 19 03:08:00 CST 2020, time=2020-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1798838, encodeId=45671e9883800, content=<a href='/topic/show?id=82ebe065192' target=_blank style='color:#2F92EE;'>#疾病发作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70651, encryptionId=82ebe065192, topicName=疾病发作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Wed Jun 17 06:08:00 CST 2020, time=2020-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271862, encodeId=160212e1862f7, content=<a href='/topic/show?id=9fef169483' target=_blank style='color:#2F92EE;'>#AAV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1694, encryptionId=9fef169483, topicName=AAV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ba7103, createdName=xuqianhua, createdTime=Mon Jul 08 02:08:00 CST 2019, time=2019-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=369244, encodeId=84cc3692442c, content=向挑战病魔的科研人员致敬!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5171668917, createdName=坚强007, createdTime=Sun Jul 07 17:42:08 CST 2019, time=2019-07-07, status=1, ipAttribution=)]
    2019-07-08 xuqianhua
  5. [GetPortalCommentsPageByObjectIdResponse(id=1856320, encodeId=c8f21856320cd, content=<a href='/topic/show?id=f32014428fc' target=_blank style='color:#2F92EE;'>#PNAS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14428, encryptionId=f32014428fc, topicName=PNAS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=08e964, createdName=drwjr, createdTime=Mon Oct 28 07:08:00 CST 2019, time=2019-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2024636, encodeId=c78e2024636a2, content=<a href='/topic/show?id=d3341696b8' target=_blank style='color:#2F92EE;'>#AAV2#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1696, encryptionId=d3341696b8, topicName=AAV2)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04ce158, createdName=lxg951, createdTime=Sun Apr 19 03:08:00 CST 2020, time=2020-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1798838, encodeId=45671e9883800, content=<a href='/topic/show?id=82ebe065192' target=_blank style='color:#2F92EE;'>#疾病发作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70651, encryptionId=82ebe065192, topicName=疾病发作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e87d405, createdName=Homburg, createdTime=Wed Jun 17 06:08:00 CST 2020, time=2020-06-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271862, encodeId=160212e1862f7, content=<a href='/topic/show?id=9fef169483' target=_blank style='color:#2F92EE;'>#AAV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1694, encryptionId=9fef169483, topicName=AAV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8ba7103, createdName=xuqianhua, createdTime=Mon Jul 08 02:08:00 CST 2019, time=2019-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=369244, encodeId=84cc3692442c, content=向挑战病魔的科研人员致敬!, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e5171668917, createdName=坚强007, createdTime=Sun Jul 07 17:42:08 CST 2019, time=2019-07-07, status=1, ipAttribution=)]
    2019-07-07 坚强007

    向挑战病魔的科研人员致敬!

    0

相关资讯

J Rheumatol:ANCA相关性血管炎中的严重感染

与背景人群相比,AAV患者的严重感染率特别高,特别是年龄较大、肾功能受损的患者。

J Rheumatol:抗中性粒细胞胞浆抗体(ANCA)相关性血管炎中的肺受累

肺部受累很常见,140例接受胸部CT检查的AAV患者中,近80%患者胸部CT异常。

Arthritis Rheumatol:ANCA相关性血管炎的流行病学:一项基于人群的20年研究

MPA和EGPA的死亡率,而不是GPA,高于一般人群;MPO-ANCA是生存率差的标志。

ANN RHEUM DIS:ANCA相关性血管炎缓解期延长治疗研究

缓解后延长硫唑嘌呤/泼尼松龙维持治疗至诊断后24个月以上能够减少48个月内的复发风险,并改善AAV的肾功能。

Ann Rheum Dis:尿表皮生长因子可以预测ANCA相关血管炎的肾脏预后

在AAV患者中,较低的uEGF/Cr水平与更严重的肾脏疾病、治疗耐药和进展为复合终点的风险更高相关。

Nat Rev Drug Discov:AAV基因治疗神经系统疾病的进展与挑战

8月10日,Nature Reviews上发表了一篇关于AAV基因治疗神经系统疾病的进展与展望,通讯作者是Voyager Therapeutics的首席科学官Dinah WY Sah。文中探讨了未来设计和开发治疗性AAV载体的关键考虑因素和挑战,并且列举了最近的临床进展。